Targeted Temperature Management With Total Liquid Ventilation After Ischemic Spinal Cord Injury

Kohlhauer, Matthias; Lidouren, Fanny; Barretto, Mariana; Micheau, Philippe; Adam, Clovis; Dhonneur, Gilles; Ghaleh, Bijan; Tissier, Renaud

doi:10.1016/j.athoracsur.2018.06.073

Cited by 4 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In experimental SCI models, nimodipine (NDP) can improve spinal blood flow and rescue hypoperfusion (77). NDP administration can significantly improve neurological recovery following spinal cord trauma or ischemia (Table I) (89). NDP was first studied in France in a potential randomized clinical trial of 160 patients within 8 h of injury: Methylprednisolone (MPSS), NDP 0.15 mg/kg/h for 2 h, then 0.03 mg/kg/h for 7 days; both MPSS and NDP or placebo (90)(91)(92).…”

Section: Pharmacological Drugs Used For the Treatment Of Sci (Table Imentioning

confidence: 99%

Acute spinal cord injury: Pathophysiology and pharmacological intervention (Review)

et al. 2021

View full text Add to dashboard Cite

Spinal cord injury (SCI) is one of the most debilitating of all the traumatic conditions that afflict individuals. For a number of years, extensive studies have been conducted to clarify the molecular mechanisms of SCI. Experimental and clinical studies have indicated that two phases, primary damage and secondary damage, are involved in SCI. The initial mechanical damage is caused by local impairment of the spinal cord. In addition, the fundamental mechanisms are associated with hyperflexion, hyperextension, axial loading and rotation. By contrast, secondary injury mechanisms are led by systemic and cellular factors, which may also be initiated by the primary injury. Although significant advances in supportive care have improved clinical outcomes in recent years, a number of studies continue to explore specific pharmacological therapies to minimize SCI. The present review summarized some important pathophysiologic mechanisms that are involved in SCI and focused on several pharmacological and non-pharmacological therapies, which have either been previously investigated or have a potential in the management of this debilitating injury in the near future.

show abstract

Section: Pharmacological Drugs Used For the Treatment Of Sci (Table Imentioning

confidence: 99%

Acute spinal cord injury: Pathophysiology and pharmacological intervention (Review)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This phenomenon is called Spinal Cord Ischemia-Reperfusion Injury (SCIRI). 1 It is a secondary injury after primary spinal cord injury, and an important factor causing nerve cell injury. It can cause quadriplegia, paraplegia and even death.…”

Section: Sirmentioning

confidence: 99%

Effect Analysis of Hyperbaric Oxygen Therapy with Methylprednisolone on Prevention of Spinal Cord Ischemia-Reperfusion Injury

Chen¹,

Fan²,

Liao³

et al. 2019

J Coll Physicians Surg Pak

View full text Add to dashboard Cite

Protective Effect of Mild Hypothermia on Spinal Cord Ischemia-Induced Delayed Paralysis and Spinal Cord Injury

et al. 2022

Neurochem Res

View full text Add to dashboard Cite

Targeted Temperature Management With Total Liquid Ventilation After Ischemic Spinal Cord Injury

Abstract: Ultrafast hypothermic TLV attenuates spinal cord injury when applied after ischemic insult. Neurological outcome was similar with targeted temperature management at either 33°C or 36°C.

Cited by 4 publications

References 38 publications

Acute spinal cord injury: Pathophysiology and pharmacological intervention (Review)

Acute spinal cord injury: Pathophysiology and pharmacological intervention (Review)

Effect Analysis of Hyperbaric Oxygen Therapy with Methylprednisolone on Prevention of Spinal Cord Ischemia-Reperfusion Injury

Protective Effect of Mild Hypothermia on Spinal Cord Ischemia-Induced Delayed Paralysis and Spinal Cord Injury

Contact Info

Product

Resources

About